SCHEMBL16183414

SCHEMBL16183414

Cc1c(-c2cccc(F)c2)ccc2c(N3CCc4cc(Cl)ccc43)nc(-c3cccnc3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 7/20 0.38
▸ CYP11B1 P15538 4/20 0.38
▸ SRD5A1 P18405 1/20 0.36
▸ MKNK1 Q9BUB5 1/20 0.35
▸ MKNK2 Q9HBH9 1/20 0.35
▸ GBA1 P04062 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ROCK1 Q13464 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ CLK4 Q9HAZ1 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183415 0.93 CYP11B2 (0.41) CYP11B2CYP11B1SRD5A1GBA1HTR2A
SCHEMBL16183411 0.93 CYP11B2 (0.42) CYP11B2CYP11B1SRD5A1GBA1HTR2A
SCHEMBL16183412 0.90 CYP11B2 (0.41) CYP11B2CYP11B1SRD5A1GBA1HTR2A
SCHEMBL16183413 0.89 CYP11B2 (0.40) CYP11B2CYP11B1SRD5A1GBA1HTR2A
SCHEMBL16183410 0.86 SRD5A1 (0.39) CYP11B2CYP11B1SRD5A1GBA1HTR2A
SCHEMBL16183390 0.84 CYP11B2 (0.44) CYP11B2CYP11B1SRD5A1GBA1ALDH1A1
SCHEMBL16183409 0.83 GBA1 (0.40) CYP11B2CYP11B1SRD5A1GBA1ALDH1A1
SCHEMBL16184013 0.83 MAPT (0.42) CYP11B2CYP11B1SRD5A1HTR2AHTR2C
SCHEMBL16183388 0.81 GBA1 (0.41) CYP11B2CYP11B1GBA1ALDH1A1GAA
SCHEMBL16183992 0.81 CYP11B2 (0.41) CYP11B2CYP11B1GBA1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CYP11B2 2204/4885CYP11B1 2235/4885SRD5A1 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback